Compare WTTR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | STOK |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 2017 | 2019 |
| Metric | WTTR | STOK |
|---|---|---|
| Price | $14.01 | $33.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $16.17 | ★ $36.10 |
| AVG Volume (30 Days) | ★ 1.8M | 616.8K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $1,528,930,000.00 | $36,555,000.00 |
| Revenue This Year | $2.32 | $428.68 |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $69.16 | ★ $42.88 |
| Revenue Growth | 120.79 | ★ 316.34 |
| 52 Week Low | $7.20 | $5.35 |
| 52 Week High | $15.45 | $40.22 |
| Indicator | WTTR | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 46.31 |
| Support Level | $10.10 | $31.60 |
| Resistance Level | $14.24 | $35.75 |
| Average True Range (ATR) | 0.54 | 2.31 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 85.33 | 10.70 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.